Sage Therapeutics to Implement Strategic Reorg, Reduce Staff

Sage Therapeutics plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of Zurzuvae for women with postpartum depression in late 2023. Following a strategic review, the company will refine pipeline development efforts with the goal of making evidence-driven investments; implement a 40% workforce reduction designed to right-size the organization; and align its leadership team structure to scale with pipeline and commercial priorities.

“Our goal is to think big, start small and scale fast as we look to launch Zurzuvae and help women suffering with PPD​. Executing on launch and our potential long-term growth catalysts requires us to allocate resources strategically,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “Part of our efforts to become a leaner and stronger company means having to reorganize our workforce…Our business fundamentals are strong, we are well capitalized, and our goal is to put Sage in a solid position to optimize commercial execution and develop our pipeline with the goal of significant value creation.” (Source: Sage Therapeutics Website, 31 August, 2023)